CASE PRESENTATION
A 68-year-old Hispanic woman presented with a third episode of cystitis. She complained of multiple episodes of dysuria, frequency and suprapubic discomfort for the past six months. She denied fevers, chills, hematuria and flank pain. There was no history of nephrolithiasis and she had no other complaints. Her symptoms responded to oral levofloxacin, administered for 14 days after each episode of infection; however, they recurred a few weeks thereafter. Her medical history was significant for diabetes mellitus that was well controlled on oral hypoglycemic agents. She did not smoke, had immigrated to the United States 45 years previously and had a negative purified protein derivative test on intake. She was married with three healthy children, was a homemaker and had no contact with animals.

On examination, the patient was afebrile, with a temperature of 37.6°C. Her blood pressure was 126/78 mmHg, heart rate was 82 beats/min and her oxygen saturation was 97% on room air. She was awake, alert and not in acute distress. Her skin was intact with no rashes or lymphadenopathy. She had clear lung fields, regular heart sounds without murmurs and soft nontender abdomen with no organomegaly. She had no renal angle tenderness and no lymphadenopathy. Her neurological examination was nonfocal.

Blood tests revealed a hemoglobin level of 97 g/L and white blood cell count of 8.4×10^9 cells/L. She had chronic kidney disease with a creatinine level of 133 μmol/L. Her liver function tests were normal. Urinalysis revealed a white blood cell count of >100 cells per high-power field, with hematuria and proteinuria. Routine urine culture was negative. A computed tomography scan of the abdomen and pelvis showed normal kidney size with no stones, and a thickened urinary bladder wall with no ascites or lymphadenopathy. The patient underwent cystoscopy and biopsy (Figures 1 and 2).

What is your diagnosis?

DIAGNOSIS
The patient’s mucosal biopsy showed multiple granulomas composed of epithelioid histiocytes and multinucleated giant cells with acid-fast bacilli consistent with Mycobacterium tuberculosis (MTB). She did not have symptoms or radiological features concerning for pulmonary tuberculosis (TB). She was diagnosed with TB cystitis and started empirically on isoniazid (INH), rifampin (RIF), ethambutol and pyrazinamide. Biopsy culture confirmed the diagnosis and grew susceptible MTB. She completed two months of all four agents and a subsequent four months of INH and RIF. She tolerated the medications well, with complete resolution of her symptoms. The fact that levofloxacin is a second-line agent for treating TB explained the short-lived improvement in the patient’s symptoms after the first two episodes of cystitis.

DISCUSSION
TB is encountered globally and is associated with high morbidity and mortality (1-3). Only 10% of TB-infected individuals will develop active disease (4,5). The remainder have latent TB infection, which will continue to be dormant for their entire lives. Immunosuppression due to HIV infection, long-term steroid use or organ transplantation, diabetes mellitus and chronic kidney disease can lead to TB reactivation (5,6).

Genitourinary tuberculosis (GUTB) is a form of extrapulmonary TB and usually results from reactivation of a latent TB infection (7). The genitourinary tract is the second most common site of extrapulmonary TB, following the lymphatic system (4,6). The kidneys are the most common location for GUTB and are infected through hematogenous seeding. From the kidneys, the bacilli may spread through the urinary tract and nearby structures, which can cause infections in the retropitoneum, adrenals, urinary collecting system, genital organs in men and pelvic organs in women (6,7). Of note, isolated renal TB is more likely to affect young women in their third decade of life (8,9).

In Canada, the rates of TB have been declining since 1970 (10). GUTB prevalence, however, has been stable (approximately 2%) (11). In 2001, for example, GUTB accounted for 1.8% of all TB cases and 6.5% of extrapulmonary TB cases (12).

Patients with GUTB can present with symptoms similar to bacterial urinary tract infection (UTI). The most common presenting symptoms include irritative voiding symptoms, flank pain and hematuria (13). Additionally, systemic symptoms, such as fever and weight loss, may be present but are typically rare. Some patients can be asymptomatic; in these cases, pyuria and/or microscopic hematuria may be evident (14). In a retrospective study, Kulchavenya et al (8) found that the majority of patients with GUTB complained of flank pain (35.2%) and dysuria (39.8%). Similarly, in a 13-year study, Singh et al (9) observed that the most common clinical presentation of GUTB was irritative voiding symptoms (66.47%).

The diagnosis of GUTB is based on the presence of TB risk factors and a long-standing history of urinary tract complaints that are often nonspecific, in addition to isolating MTB in urine or urinary tract tissue biopsy (7,15). In the appropriate setting, pyuria in the absence of bacterial growth on routine microbiological studies should raise concerns for an underlying GUTB (6,7).

Isolating MTB in urine has been used as the primary test in the diagnosis of GUTB (16). The sensitivity of urine culture in conventional culture media has been reported to be between 80% to 97% (15). Recently, nucleic acid amplification techniques, such as polymerase chain reaction (PCR), have been used more commonly for the detection of MTB (12). PCR is highly sensitive and specific in detecting MTB in urine, with reported sensitivity and specificity of up to 88% and 95%, respectively (4,15). Singh et al (9) noted that PCR testing had a higher positivity rate (67.7%) when compared with urine acid-fast bacillus staining (41.6%) and urine MTB culture (55.4%).

The purified protein derivative skin test has been traditionally used to evaluate previous exposure to TB. A positive skin test can support the diagnosis of TB; however, a negative skin test does not rule out pulmonary or extrapulmonary TB such as GUTB (17). Interferon-gamma release assays are also used for diagnosing latent tuberculosis infection. The specificity is >95% and the sensitivity is 80% to 90% (18,19); however, there are limited data regarding the utility of interferon-gamma release assays for diagnosing GUTB (20).

1Department of Internal Medicine, Texas Tech University Health Sciences Center; 2Amarillo Pathology Group; 3Section of Infectious Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA

Correspondence: Dr Faisal A Khasawneh, Section of Infectious Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, 1400 South Coulter Street, Amarillo, Texas 79106, USA. Telephone 806-414-9110, fax 806-354-5764, email: faisal.khasawneh@ttuhsc.edu

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com
Radiographic studies, including intravenous urography (IVU), plain abdominal radiography, ultrasonography, computed tomography and magnetic resonance imaging, can provide important clues in the diagnosis of GUTB. IVU was considered to be the gold-standard test in the diagnosis of early GUTB because it provides anatomical as well as functional details of the kidneys (1,15). IVU can show calyceal erosions (a ‘moth-eaten’ appearance), which later progresses to papillary necrosis (21). Plain abdominal radiography can show renal calcification; however, this is only observed in 24% to 44% of GUTB cases (22). Focal and diffuse areas of lower echogenicity can be evident on kidney ultrasonography (21). Other features of GUTB observed on ultrasonography include calcifications, ureteral thickening, parenchymal masses and cavities (1). Computed tomography, however, is considered to be more sensitive than ultrasonography for the diagnosis of GUTB (21,23), and can also help in evaluating renal function. Magnetic resonance imaging provides excellent details of kidney morphology and allows for the visualization of ureters (15). It has been used in challenging cases in which computed tomography and ultrasound images were inconclusive (24).

GUTB treatment is similar to that of pulmonary TB. It consists of the four first-line anti-TB drugs (INH, RIF, pyrazinamide and ethambutol) given for two months followed by INH and RIF given for four more months (25,26). INH and RIF are considered to be the most active drugs in the regimen (27,28). Second-line TB drugs, such as fluoroquinolones (FQs), are considered when the infection is most active drugs in the regimen (27,28). Second-line TB drugs, such as fluoroquinolones (FQs), are considered when the infection is caused by drug-resistant MTB, when the patient fails to achieve clinical response or when the patient experiences toxicity attributed to the standard treatment regimen (29). Surgical intervention should not be considered until medical therapy has failed for at least four to six weeks (17). Unless used to drain an abscess or relieve obstructive uropathy, surgical intervention should not be considered until medical therapy has been provided for at least four to six weeks (29).

CONCLUSION

GUTB is the second most common form of extrapulmonary TB. Its symptoms and signs are nonspecific and can mimic those of bacterial UTI. Sterile puyria and recurrent UTI that is poorly responsive to antibiopic therapy should raise suspicion for this mycobacterial infection. Giving FQs in GUTB misdiagnosed as bacterial UTI can delay TB diagnosis and may lead to mycobacterial FQ resistance.

REFERENCES

16. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.